Network meta-analysis of pembrolizumab as monotherapy and in combination with chemotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.

Pembrolizumab monotherapy or in combination with chemotherapy is approved as first-line treatment in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on improved overall survival (OS) versus EXTREME regimen in the KEYNOTE-048 trial. The clinical outcomes of pembrolizumab...

Descripción completa

Detalles Bibliográficos

Publicado en:	JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde Vol. 16; no. 1; pp. 25 - 65
Autores principales:	Mojebi, Ali, Ramakrishnan, Karthik, Ayers, Dieter, Keeping, Sam, Borse, Rebekah, Chirovsky, Diana
Formato:	Artículo
Publicado:	JBES: Brazilian Journal of Health Economics abr2024
Materias:	Squamous cell carcinoma Combination drug therapy Pembrolizumab Bayesian analysis Overall survival
Acceso en línea:	Ver este registro en EBSCOhost